drugset / Trial / NCT00641589
A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
Phase 1
Completed
40 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Centocor Ortho Biotech Services, L.L.C. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to describe how four different dosing regimens of PROCRIT (epoetin alfa) are utilized in patients with anemia due to non-dialysis chronic kidney disease (CKD).
Timeline
- Start
- 2006-01
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 50 iu/kg | — |
| Subject | epoetin alfa | Protein / enzyme biologic | 10000 iu | — |
| Subject | epoetin alfa | Protein / enzyme biologic | 20000 iu | — |
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | — |